Comprehensive’s Radiation Division Expands
With the addition of Samual R. Francis, MD, the radiation oncology team at Comprehensive Cancer Centers of Nevada is expanding. Dr. Francis comes to Comprehensive from the Radiation Oncology Residency Program at the University of Utah Huntsman Cancer Hospital, where he served as chief resident in 2017. His research and findings have appeared in several industry publications, including the Journal of Applied Clinical Medical Physics, International Journal of Radiation Oncology, Biology, Physics, and the Journal of Clinical Oncology. He also won the 2018 Radiological Society of North America’s Roentgen Resident/ Fellow Research Award.
Dr. Francis has extensive training using external beam treatment modalities as well as brachytherapy. He also has expertise in advanced CT simulation, treatment planning, and Image-Guided Radiotherapy (IGRT).
Dr. Francis joins eight radiation oncologists at Comprehensive who all use the most advanced treatment planning systems and state-of-the-art radiation technology to deliver internal and external radiation, which helps prevent cancerous cells from growing or dividing and potentially eliminating them.
Innovative technologies offered at Comprehensive include IGRT. Intensity Modulated Radiation Therapy (IMRT), High Dose Rate Brachytherapy (HDR), Accelerated Partial Breast Irradiation (APBI), Stereotactic Radiosurgery (SRS), Volumetric Modulated Arc Therapy (VMAT) and CyberKnife® Radiosurgery, which is exclusive to Comprehensive. Radiopharmaceuticals agents are also available to patients of Comprehensive and can be used as diagnostic and therapeutic agents. Radiopharmaceuticals include Xofigo and Zevalin.
A promising new therapy for those with advanced stage prostate cancer – a radionuclide treatment known as 177Lu-PSMA-617 – is currently in Phase III of testing at Comprehensive. The intravenous therapy kills a cancer that is dividing by destroying its ability for cell division. The patients who have received this treatment so far are tolerating it well and with minimal side effects.
Axumin PET Scans are now offered at Comprehensive to achieve early detection of recurrent prostate cancer after surgery or radiation. Axumin can detect recurrent instances of the disease with PSA levels less than 10 and sometimes much lower, which is the reason this scan is such an important development.
Comprehensive’s Radiation Oncology Division earned a three-year term of accreditation from the American College of Radiology, making it the only oncology practice in Southern Nevada to receive accreditation for seven consecutive three-year terms.